45 results about "ERCC2" patented technology

The invention relates to tumor susceptibility 62 genes and application thereof. The tumor susceptibility 62 genes comprise PTEN, STK11, CDH1, TP53, BRCA1, BRCA2, PALB2, CHEK2, ATM, BRIP1, NBN, RAD51C, MLH1, MSH2, MSH6, PMS2, BARD1, RAD51D, MRE11A, MUTYH, PMS1, RAD50, XRCC2, AKT1, PIK3CA, FANCC, RECQL, CCND1, ERBB2, ESR1, GATA3, FGFR1, MAP2K4, MAP3K1, BAI3, CTNNB1, BRAF, KRAS, CTNNA1, EPCAM, APC, BLM, SMAD4, BMPR1A, POLD1, POLE, AXIN2, MEN1, KIT, EGFR, EZH2, PRF1, CDKN2A, CDK4, BAP1, RB1, ERCC2, VHL, MET, FH, FLCN and RET. The detection of the genes can be used for evaluating tumor susceptibility.

Methods are disclosed for genetically counseling a person based on one or more polymorphisms in his or her genes that sensitize him or her to toxic agents. Methods are also disclosed for genetically screening a group of individuals and / or a human population, based on, for example, ethnicity, race, religion or geographic region, to identify individuals with such polymorphisms for counseling. The methods can be used to counsel a person who has not been genetically tested for polymorphisms but who might have increased risk for sensitivity to toxic agents due to his or her membership in a particular group and / or population. The methods use correlations between genotypes of polymorphic alleles in a panel of cell lines and sensitivity of the cell lines to toxic agents. As examples, the methods are used to identify genotypes of allelic forms of the genes TP53, OGG1, ERCC2, XRCC1, and NOS3 that increase sensitivity or resistance of cells to toxic agents.

The invention discloses a reagent kit for detecting lung cancer susceptibility, comprising a common component for fluorescence quantitative PCR detection, and a specific primer pair and a specific fluorescent probe which detect the NO. rs1136410 SNP site of PARP1 gene, the NO. rs1048943 SNP site of CYP1A1 gene, the NO. rs25487 SNP site of XRCC1 gene, the NO. rs13181 SNP site of ERCC2 gene and the NO. rs1799793 SNP site of ERCC2 gene at the same time. The reagent kit can predict the lung cancer susceptibility of individual through detecting the SNPs site genotype of PARP1 gene, CYP1A1 gene, XRCC1 gene and ERCC2 gene of individual at the same time.

The invention relates to a real-time PCR detecting method of tumor-associated gene mutation and reagent system, belonging to medicine curative effect detecting technical field. The tumour repair genes XRCC3, ERCC1 and ERCC2 associated with the tumour individualized theraphy are used as target genes to detect, and the customed designed special oligonucleotide primer sequence, hydrolysis probe and Taqman-MGB detection agent system are used and using real-time quantitative PCR method, therefore the mutation of special site of the tumor-associated gene is detected wherein the agent system is just the real-time quantitative PCR agent system comprising any oligonucleotide primer sequence and probe. The method can be used for effect detection of the clinical individualized medication scheme.

The invention discloses an agent box for detecting idiogenetics gene repair capacity. The agent box comprises specificity primer pair and specificity fluorescent detecting probe pair for detecting synchronously number rs1136410 SNP site on multi-poly ADP ribose transferase gene (PARP1), number rs1799782 and rs25487 SNP site on human beings X ray intervein complementation repair gene (XRCC1), number rs1799793 and rs13181 on cutting repair complexes gene (ERCC2), general component for detecting fluorescent definite quantity PCR etc.. The agent box of the invention assesses idiogenetics gene repair capacity by detecting synchronously mononucleotide polymorphism site gene type correlative closely to idiogenetics gene repair capacity.

The invention discloses a method for DNA damage repair capacity inheritance risk assessment which is characterized in that: by simultaneously detecting and analyzing carrying types of a PARP1 gene, an XRCC1 gene, an ERCC2 and an SNPs locus gene of an individual, the method provides all examinees with personalized health guidance of inheritance risk assessment and related disease risk aversion of DNA damage repair capacity. The method has the advantages that: an intervention measure can be taken before a gene damage happens, thereby avoiding the gene damage further to reduce the incidence of disease and the death rate of diseases such as tumor diseases related to the gene damage; the method analyzes a tumor pathogenic mechanism from a molecular mechanism, and can be used for the formulation of molecular cancer epidemiology investment and tumor prevention measures.

The invention is encompassed in the technical sector of lung cancer treatment with antitumor drugs, and it specifically develops a diagnostic device which allows treating each patient with the most effective drug according to the polymorphism they show for the XPD gene. The assay device of the invention is based on the polymorphic variants of the XPD gene at exon 23 (A-C, Lys 751 Gln) and at exon 10 (G-A, Asp312Asn) and on the development of specific primers which allow detecting said polymorphisms by PCR or by means of automatic DNA sequencing.

The present invention discloses a reagent kit which detects the genetic susceptibility of the synthetic disease of adult woman. The reagent kit comprises a specific primer pair and a specific fluorescent probe pairs which simultaneously detects the SNP polymorphic genotype on the genes of CYBA, CAT, LPL, LEP, ADIPOQ, SOD3, IL3, NOS3, CTLA4, ENOS, ESR2, ERCC1, MTHFR, MS4A2, XRCC1, ALDH2, TNFA, MTR, CCL5, COMT, GSTP1, PPARG, PARP1, OPG, VDR, PON1, ABCA1, MTRR, ERCC2, AT1R, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1, IL6, CYP2A13, CBS, a routine component which is used for the fluorescent quantitative PCR testing and the like. The reagent kit of the invention evaluates the genetic susceptibility of the synthetic disease of adult woman through simultaneously detecting the mononucleotide polymorphism site genotype which is closely linked to the genetic susceptibility of the synthetic disease of adult woman.

The invention discloses a kit that is used for detecting the genetic predisposition of wine and tobacco damages. The kit comprises particularity primer pairs and particularity fluorescent probe pairs that are used for simultaneously detecting 16 SNP polymorphism genotypes on the genes of ADH2, ALDH2, CYP1A1, CYP2A13, CYP2E1, ENOS, ERCC2, GSTM1, GSTP1, GSTT1, MTHFR, NQO1 and XRCC1 and a routine component that is used for fluorescent quantitative PCR detection, etc. The kit of the invention evaluates the genetic predisposition of wine and tobacco damages by simultaneously detecting the 16 mononucleotide polymorphism locus genotypes that are closely related with the genetic predisposition of wine and tobacco damages.

The present invention discloses a reagent kit for detecting the susceptibility of the lung cancer. The reagent kit comprises a specific primer pair which detects the SNP locus of No. rs1799793 and the SNP locus of No. rs13181 on an ERCC2 gene synchronously, a specific fluorescent probe, and a conventional component which is used for the fluorescent quantitative PCR detection, etc. The reagent kit of the present invention predicts the susceptibility of the individual to the lung cancer by detecting the gene carrying type of the two different SNPs loci on the ERCC2 gene of the individual synchronously.

The present invention provides a kit for detecting genetic predisposition of adult male syndrome. The kit includes specific primer pairs and specific fluorescent probe pairs for detecting 48 SNP polymorphism genotypes on the genes LPL, TNF-alpha, LEP, ADIPOQ, SOD3, IL3, CTLA4, ENOS, ESR2, ERCC1, MTHFR, MS4A2, XRCC1, ALDH2, TNFA, MTR, CCL5, COMT, GSTP1, PPARG, PARP1, OPG, VDR, PON1, ABCA1, MTRR, ERCC2, AT1R, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1, IL6, CYP2A13 at the same time, and normal components for FQ-PCR detection. The kit of the invention evaluates the genetic predisposition of adult male syndrome by detecting the genotypes of the 48 SNP polymorphism sites at the same time which is tightly relative to the genetic predisposition of adult male syndrome.

The present invention discloses a reagent kit to detect lung cancer susceptibility, which comprises a fluorescence probe to synchronously detect specificity tracers and specificity of No. rs1048943 SNP locus on gene CYP1A1 and No. rs13181 SNP locus on gene ERCC2, and a normal assembly to detect fluorescence quantitative PCR and so on. The reagent kit of the present invention synchronously detects and analyzes individual SNPs locus gene carrying type on gene CYP1A1 and ERCC2 to predict susceptibility of the individual to lung cancer.

The present invention provides a kit of detecting genetic predisposition of children syndrome. The kit includes specific primer pairs and specific fluorescent probe pairs for detecting 28 SNP polymorphism genotypes on the genes NOS3, CTLA4, ENOS, ERCC1, ERCC2, MTHFR, MTRR, MTR, MS4A2, XRCC1, ALDH2, TNFA, CCL5, PARP1, OPG, VDR, PON1, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1 at the same time, and normal components for FQ-PCR detection. The kit of the invention evaluates the genetic predisposition of children syndrome by detecting the genotypes of the 28 SNP polymorphism sites at the same time which is tightly relative to the genetic predisposition of children syndrome.

The invention discloses a regent box for detecting the susceptibility to lung cancer, comprising a specific primer and a specific fluorescent probe which are capable of synchronously detecting an rs1136410 SNP locus on an PARP1 gene, an rs25487 SNP locus on a XRCC1 gene and an rs13181 SNP locus and an rs1799793 SNP locus on an ERCC2 gene, and common components for fluorescent quantitative detection of PCR. The reagent box of invention predicts the susceptibility to lung cancer of an individual by detecting the genotype of genes on the SNP loci of the PARP1 gene, the XRCC1 gene and the ERCC2 gene of the individual.

Evofosfamide (TH-302) or an analog thereof has a specific inhibitory effect on a cell having a specific gene mutation, in particular on a DNA repair-damaged cell. The cell or tissue has at least one or more gene mutations in BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2,XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP, and ERCC5. For this, a medical use of evofosfamide (TH-302) or an analog thereof in treating tumors or cancer in a cancer patient having the specific gene mutation(s) is provided.

The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs25487 SNP site of XRCC1 gene and no. rs1799793 SNP site of ERCC2 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual XRCC1 and ERCC2 gene.

The present invention discloses a kit for detecting pulmonary carcinoma susceptibility. Said kit includes specific primer pair and specific fluorescent probe for detecting SNP site of position 156 in ERCC2 gene SEQ ID NO.1 and conventional component for making fluorescent quantitative PCR detection.

The invention provide methods for early detection of a reduced risk of developing cancer, which comprises detecting the absence of a series of genetic polymorphisms associated with a predisposition of developing cancer, including the polymorphisms of the genes BRCA1, BRCA2, CARD15 (NOD2), CHEK2, CDKN2A (P16), CYP1B1, FGFR2 (KGFR2), MAP3K1 (MEKK1), p53 (TP53), TNRC9, XPD (ERCC2) and the genetic marker Rs6983267, in a biological sample from the analyzed subject, wherein the absence of the genetic polymorphisms is indicative of significantly decreased risk of developing, at least, breast cancer.

The invention discloses a kind of reagent box for detection of susceptibility to esophageal cancer. The reagent box comprises of specific primer pairs for the detection of the 146th SNP locus in ERCC2 SEQ ID NO: 1 of XRCC1 gene, conventional components for fluorescence quantitative PCR. The reagent box by this invention can predict individual susceptibility to esophageal cancer through the detection of individual portable type of SNP locus gene in XRCC1 gene.

The present invention discloses a kit used for inspection of susceptibility of lung cancer. The kit comprises not only a specific primer couple and a specific fluorescent probe, which are capable of inspecting at the same time the site SNP of No. rs25487 of gene XRCC1, both the site SNP of No. rs13181 and the site SNP of No. rs1799793 of gene ERCC2, but also a standard component used for fluorescent quantitative PCR. The kit provided by the present invention predicts the individual susceptibility to lung cancer through mutual analysis on the gene type on the site of SNPs of both the gene XRCC1 and gene ERCC2.

The invention discloses a regent box for detecting the susceptibility to lung cancer, comprising a specific primer and a specific fluorescent probe which are capable of synchronously detecting an rs1048943 SNP locus on a CYPIA1 gene, an rs1136410 SNP locus on an PARP1gene, an rs13181 SNP locus and an rs1799793 SNP locus on an ERCC2 gene, and common components for fluorescent quantitative detection of PCR. The reagent box of invention predicts the susceptibility to lung cancer of an individual by detecting the genotype of genes on the SNP loci of the CYPIA1 gene, the PARP1 gene and the ERCC2 gene of the individual.

The present invention discloses a reagent kit for detecting the susceptibility of the lung cancer. The reagent kit comprises a specific primer pair which detects the SNP locus of No. rs1136410 on a PARP1 gene, the SNP locus of No. rs1799793 on an ERCC2 gene and the SNP locus of No. rs25487 on a XRCC1 gene synchronously, a specific fluorescent probe, and a conventional component which is used for the fluorescent quantitative PCR detection, etc. The reagent kit of the present invention predicts the susceptibility of the individual to the lung cancer through detecting the gene carrying type of the SNPs loci on the PARP1 gene, the ERCC2 gene and the XRCC1 gene of the individual synchronously.

The present invention discloses a reagent kit for detecting the susceptibility of the lung cancer. The reagent kit comprises a specific primer pair which detects the SNP locus of No. rs1136410 on a PARP1 gene, the SNP locus of No. rs13181 and the SNP locus of No. rs1799793 on an ERCC2 gene synchronously, a specific fluorescent probe, and a conventional component which is used for the fluorescent quantitative PCR detection, etc. The reagent kit of the present invention predicts the susceptibility of the individual to the lung cancer through detecting the gene carrying type of the SNPs loci on the PARP1 gene, the ERCC2 gene and the XRCC1 gene of the individual synchronously.

The present invention discloses a reagent kit to detect lung cancer susceptibility, which comprises a fluorescence probe to synchronously detect specificity tracers and specificity of No. rs1799793 SNP locus on gene ERCC2 and No. rs1136410 SNP locus on gene PARP1, and a normal assembly to detect fluorescence quantitative PCR and so on. The reagent kit of the present invention synchronously detects and analyzes individual SNPs locus gene carrying type on gene ERCC2 and PARP1 to predict susceptibility of the individual to lung cancer.

The invention discloses an excision repair cross complementation group 2 (ERCC2) gene mutation detection liquid chip and specific primers. The liquid chip mainly comprises ASPE primers and each one of the primers comprises a tag sequence at the end 5' and a specific primer sequence at the end 3' aiming at a target gene mutation site. The specific primer sequence comprises sequences shown in the formulas of SEQ ID NO. 9 and SEQ ID NO. 10 aiming at the G934A site, sequences shown in the formulas of SEQ ID NO. 11 and SEQ ID NO. 12 aiming at the T128G site, sequences shown in the formulas of SEQ ID NO. 13 and SEQ ID NO. 14 aiming at the C2133T site, and sequences shown in the formulas of SEQ ID NO. 15 and SEQ ID NO. 16 aiming at the A396C site. The liquid chip also comprises anti-tag sequence-coated microspheres and amplification primers. The detection result of the detection liquid chip and the detection result of the sequencing method have a coincidence rate of 100%. The ERCC2 gene mutation detection liquid chip realizes individual or parallel detection of multiple wild type and mutant type sites.

The invention discloses a kit used for detecting the genetic susceptibility of male tumor diseases. The kit comprises a specific primer pair which detects genotypes of sixteen sites of single nucleotide polymorphism (SNP) in CCND1, CYP2A13, CYP1A1, CYP2E1, ERCC2, GSTM1, GSTP1, GSTT1, MTHFR, NQO1, PARP1, XRCC1 and ERCC1 simultaneously and specified fluorescent probe pairs, conventional components used in fluorescence quantitative PCR detecting, and the like. The kit of the invention evaluates the genetic susceptibility of male tumor diseases by detecting genotypes of sixteen sites of single nucleotide polymorphism which is closely related to the genetic susceptibility of male tumor diseases.

The present invention discloses a kit for detecting pulmonary carcinoma susceptibility. Said kit includes specific primer pair and specific fluorescent probe for detecting SNP site of position 156 in ERCC2 gene SEQ ID NO.1 and conventional component for making fluorescent quantitative PCR detection.

The invention provides a primer for detecting the ERCC2 gene polymorphism. The primer comprises a PCR amplification primer and an SNaPshot PCR primer. The invention belongs to the technical field of biological detection. The primer provided by the invention can realize specific detection of the ERCC2 gene polymorphism, and has good accuracy.

The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs1048943 SNP site of CYP1A1 gene and no. rs1799793 SNP site of ERCC2 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual CYP1A1 and ERCC2 gene.